It has been reported that anti-PD-1 immunotherapy activates T cells in tumor-draining LNs, which contribute to the antitumor response.29 We further investigated the impact of CLN resection on the antitumor efficacy of anti-PD-1/anti-CTLA-4 therapy. The gene discussed is CTLA4; the disease is neoplasm.